Publications

Export 92 results:
Auteur Title [ Type(Desc)] Année
Filtres: Auteur is Pedro Rosa-Neto  [Enlever les filtres]
Journal Article
Zimmer ER, Parent MJ, Souza DG, Leuzy A, Lecrux C, Kim H-I, Gauthier S, Pellerin L, Hamel E, Rosa-Neto P.  2017.  [(18)F]FDG PET signal is driven by astroglial glutamate transport.. Nat Neurosci. 20(3):393-395.
Pascoal TA, Therriault J, Benedet AL, Savard M, Lussier FZ, Chamoun M, Tissot C, Qureshi MNaveed Iqb, Kang MSu, Mathotaarachchi S et al..  2020.  18F-MK-6240 PET for early and late detection of neurofibrillary tangles.. Brain. 143(9):2818-2830.
Pascoal TA, Mathotaarachchi S, Shin M, Park AYeon, Mohades S, Benedet AL, Kang MSu, Massarweh G, Soucy J-P, Gauthier S et al..  2018.  Amyloid and tau signatures of brain metabolic decline in preclinical Alzheimer's disease.. Eur J Nucl Med Mol Imaging. 45(6):1021-1030.
Kang MSu, Aliaga AAliaga, Shin M, Mathotaarachchi S, Benedet AL, Pascoal TA, Therriault J, Chamoun M, Savard M, Devenyi GA et al..  2020.  Amyloid-beta modulates the association between neurofilament light chain and brain atrophy in Alzheimer's disease.. Mol Psychiatry.
Pascoal TA, Mathotaarachchi S, Mohades S, Benedet AL, Chung C-O, Shin M, Wang S, Beaudry T, Kang MS, Soucy J-P et al..  2016.  Amyloid-β and hyperphosphorylated tau synergy drives metabolic decline in preclinical Alzheimer's disease.. Mol Psychiatry.
Ongali B, Nicolakakis N, Tong X-K, Aboulkassim T, Papadopoulos P, Rosa-Neto P, Lecrux C, Imboden H, Hamel E.  2014.  Angiotensin II type 1 receptor blocker losartan prevents and rescues cerebrovascular, neuropathological and cognitive deficits in an Alzheimer's disease model.. Neurobiol Dis. 68:126-36.
Therriault J, Ng KPin, Pascoal TA, Mathotaarachchi S, Kang MSu, Struyfs H, Shin M, Benedet AL, Walpola IC, Nair V et al..  2018.  Anosognosia predicts default mode network hypometabolism and clinical progression to dementia.. Neurology. 90(11):e932-e939.
Ba M, Kong M, Li X, Ng KPin, Rosa-Neto P, Gauthier S.  2016.  Is ApoE ɛ 4 a good biomarker for amyloid pathology in late onset Alzheimer's disease? Transl Neurodegener. 5:20.
Therriault J, Benedet AL, Pascoal TA, Mathotaarachchi S, Savard M, Chamoun M, Thomas É, Kang MSu, Lussier F, Tissot C et al..  2020.  APOEε4 potentiates the relationship between amyloid-β and tau pathologies.. Mol Psychiatry.
Miron J, Picard C, Lafaille-Magnan M-E, Savard M, Labonte A, Breitner JCS, Rosa-Neto P, Auld D, Poirier J.  2019.  Association of TLR4 with Alzheimer's disease risk and presymptomatic biomarkers of inflammation.. Alzheimers Dement. 15(7):951-960.
Carter SF, Herholz K, Rosa-Neto P, Pellerin L, Nordberg A, Zimmer ER.  2019.  Astrocyte Biomarkers in Alzheimer's Disease.. Trends Mol Med.
Gauthier S, Ng KPin, Pascoal TA, Mathotaarachchi S, Chung C-O, Benedetti AL, Shin M, Kang MSu, Li X, Ba M et al..  2017.  Author response: Neuropsychiatric symptoms predict hypometabolism in preclinical Alzheimer disease.. Neurology. 89(18):1931.
Liebsch F, Kulic L, Teunissen C, Shobo A, Ulku I, Engelschalt V, Hancock MA, van der Flier WM, Kunach P, Rosa-Neto P et al..  2019.  Aβ34 is a BACE1-derived degradation intermediate associated with amyloid clearance and Alzheimer's disease progression.. Nat Commun. 10(1):2240.
Meyer P-F, Savard M, Poirier J, Labonte A, Rosa-Neto P, Weitz TM, Town T, Breitner JCS.  2018.  Bi-directional Association of Cerebrospinal Fluid Immune Markers with Stage of Alzheimer's Disease Pathogenesis.. J Alzheimers Dis. 63(2):577-590.
Laforce R, Rosa-Neto P, Soucy J-P, Rabinovici GD, Dubois B, Gauthier S.  2016.  Canadian Consensus Guidelines on Use of Amyloid Imaging in Canada: Update and Future Directions from the Specialized Task Force on Amyloid imaging in Canada.. Can J Neurol Sci. 43(4):503-12.
DuBois JM, Rousset OG, Rowley J, Porras-Betancourt M, Reader AJ, Labbe A, Massarweh G, Soucy J-P, Rosa-Neto P, Kobayashi E.  2016.  Characterization of age/sex and the regional distribution of mGluR5 availability in the healthy human brain measured by high-resolution [(11)C]ABP688 PET.. Eur J Nucl Med Mol Imaging. 43(1):152-62.
Li X, Ba M, Ng KPin, Mathotaarachchi S, Pascoal TA, Rosa-Neto P, Gauthier S.  2018.  Characterizing biomarker features of cognitively normal individuals with ventriculomegaly.. Alzheimers Dement (Amst). 10:12-21.
[Anonymous].  2020.  Cholinergic dysfunction in the dorsal striatum promotes habit formation and maladaptive eating.. J Clin Invest. 130(12):6616-6630.
Sheynin Y, Rosa-Neto P, Hess RF, Vaucher E.  2020.  Cholinergic Modulation of Binocular Vision.. J Neurosci. 40(27):5208-5213.
Chamoun M, Huppé-Gourgues F, Legault I, Rosa-Neto P, Dumbrava D, Faubert J, Vaucher E.  2017.  Cholinergic Potentiation Improves Perceptual-Cognitive Training of Healthy Young Adults in Three Dimensional Multiple Object Tracking.. Front Hum Neurosci. 11:128.
Tam A, Dansereau C, Badhwar AP, Orban P, Belleville S, Chertkow H, Dagher A, Hanganu A, Monchi O, Rosa-Neto P et al..  2015.  Common Effects of Amnestic Mild Cognitive Impairment on Resting-State Connectivity Across Four Independent Studies.. Front Aging Neurosci. 7:242.
Engelborghs S, Niemantsverdriet E, Struyfs H, Blennow K, Brouns R, Comabella M, Dujmovic I, van der Flier W, Frölich L, Galimberti D et al..  2017.  Consensus guidelines for lumbar puncture in patients with neurological diseases.. Alzheimers Dement (Amst). 8:111-126.
Jiang L, Oualkacha K, Didelez V, Ciampi A, Rosa-Neto P, Benedet AL, Mathotaarachchi S, Richards JBrent, Greenwood CMT.  2019.  Constrained instruments and their application to Mendelian randomization with pleiotropy.. Genet Epidemiol.
Tam A, Dansereau C, Badhwar AP, Orban P, Belleville S, Chertkow H, Dagher A, Hanganu A, Monchi O, Rosa-Neto P et al..  2016.  A dataset of multiresolution functional brain parcellations in an elderly population with no or mild cognitive impairment.. Data Brief. 9:1122-1129.
Tuwaig M, Savard M, Jutras B, Poirier J, D Collins L, Rosa-Neto P, Fontaine D, Breitner JCS.  2017.  Deficit in Central Auditory Processing as a Biomarker of Pre-Clinical Alzheimer's Disease.. J Alzheimers Dis. 60(4):1589-1600.

Pages